A Therapeutic Her2/neu Vaccine Targeting Dendritic Cells Preferentially Inhibits the Growth of Low Her2/neu–Expressing Tumor in HLA-A2 Transgenic Mice

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Clinical Cancer Research

• Publication date

  2016-03-22

• Fields of study

  Medicine

• Identifiers
  DOI 10.1158/1078-0432.CCR-16-0044PMID 27006496
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Genomic analysis reveals that immune function genes are strongly linked to clinical outcome in the North Central Cancer Treatment Group n9831 Adjuvant Trastuzumab Trial.

  2015cited by this paper
• Are immune signatures a worthwhile tool for decision making in early-stage human epidermal growth factor receptor 2-positive breast cancer?

  2015cited by this paper
• CD4+ T-Helper Type 1 Cytokines and Trastuzumab Facilitate CD8+ T-cell Targeting of HER2/neu–Expressing Cancers

  2015cited by this paper
• Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer.

  2015cited by this paper
• Clinical validation of IFNγ/IL-10 and IFNγ/IL-2 FluoroSpot assays for the detection of Tr1 T cells and influenza vaccine monitoring in humans

  2014cited by this paper
• Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial.

  2014cited by this paper
• A Feasibility Study of Cyclophosphamide, Trastuzumab, and an Allogeneic GM-CSF–Secreting Breast Tumor Vaccine for HER2+ Metastatic Breast Cancer

  2014cited by this paper
• The HER2 peptide nelipepimut-S (E75) vaccine (NeuVax™) in breast cancer patients at risk for recurrence: correlation of immunologic data with clinical response.

  2014cited by this paper
• PD-1 blockade induces responses by inhibiting adaptive immune resistance

  2014cited by this paper
• Final report of the phase I/II clinical trial of the E75 (nelipepimut-S) vaccine with booster inoculations to prevent disease recurrence in high-risk breast cancer patients.

  2014cited by this paper
• Enzymatic Discovery of a HER-2/neu Epitope That Generates Cross-Reactive T Cells

  2013cited by this paper
• HER2 and breast cancer stem cells: more than meets the eye.

  2013cited by this paper
• Mucosal Imprinting of Vaccine-Induced CD8+ T Cells Is Crucial to Inhibit the Growth of Mucosal Tumors

  2013cited by this paper
• Expression of MHC Class I on breast cancer cells correlates inversely with HER2 expression

  2012cited by this paper
• Targeting of the non-mutated tumor antigen HER2/neu to mature dendritic cells induces an integrated immune response that protects against breast cancer in mice

  2012cited by this paper
• Clinical trial results of the HER‐2/neu (E75) vaccine to prevent breast cancer recurrence in high‐risk patients

  2012influential reference
• Comprehensive analysis of current approaches to inhibit regulatory T cells in cancer

  2012cited by this paper
• Redirected T cells that target pancreatic adenocarcinoma antigens eliminate tumors and metastases in mice.

  2012cited by this paper
• T cell recognition of HLA‐A2 restricted tumor antigens is impaired by the oncogene HER2

  2011cited by this paper
• Use of booster inoculations to sustain the clinical effect of an adjuvant breast cancer vaccine

  2011cited by this paper
• T-bet expression in intratumoral lymphoid structures after neoadjuvant trastuzumab plus docetaxel for HER2-overexpressing breast carcinoma predicts survival

  2011cited by this paper
• A CCR4 antagonist combined with vaccines induces antigen-specific CD8+ T cells and tumor immunity against self antigens.

  2011cited by this paper
• gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma.

  2011cited by this paper
• Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2.

  2010cited by this paper
• The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity.

  2010cited by this paper
• Clinical and immunologic responses of HLA-A3+ breast cancer patients vaccinated with the HER2/neu-derived peptide vaccine, E75, in a phase I/II clinical trial.

  2010cited by this paper
• Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia.

  2009cited by this paper
• Concurrent trastuzumab and HER2/neu-specific vaccination in patients with metastatic breast cancer.

  2009cited by this paper
• Timed sequential treatment with cyclophosphamide, doxorubicin, and an allogeneic granulocyte-macrophage colony-stimulating factor-secreting breast tumor vaccine: a chemotherapy dose-ranging factorial study of safety and immune activation.

  2009cited by this paper
• Antibody association with HER-2/neu-targeted vaccine enhances CD8 T cell responses in mice through Fc-mediated activation of DCs.

  2008cited by this paper
• CpG Oligodeoxynucleotides Alter Lymphocyte and Dendritic Cell Trafficking in Humans

  2008cited by this paper
• Combined Clinical Trial Results of a HER2/neu (E75) Vaccine for the Prevention of Recurrence in High-Risk Breast Cancer Patients: U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02

  2008cited by this paper
• B Subunit of Shiga Toxin-Based Vaccines Synergize with α-Galactosylceramide to Break Tolerance against Self Antigen and Elicit Antiviral Immunity1

  2007cited by this paper
• Investigating the Combination of Trastuzumab and HER2/neu Peptide Vaccines for the Treatment of Breast Cancer

  2006cited by this paper
• Cytotoxic effect of Shiga toxin-2 holotoxin and its B subunit on human renal tubular epithelial cells.

  2006cited by this paper
• Correspondence to Creydt VP et al., Cytotoxic effect of Shiga toxin-2 holotoxin and its B subunit on human renal tubular epithelial cells, Microbes Infect. 8(2) (2006) 410-419.

  2006cited by this paper
• Vaccination with a HER2/neu peptide induces intra- and inter-antigenic epitope spreading in patients with early stage breast cancer.

  2006cited by this paper
• Analysis of naïve and memory CD4 and CD8 T cell populations in breast cancer patients receiving a HER2/neu peptide (E75) and GM-CSF vaccine

  2006cited by this paper
• Clinical trial results of a HER2/neu (E75) vaccine to prevent recurrence in high-risk breast cancer patients.

  2005cited by this paper
• Development of cancer vaccines to activate cytotoxic T lymphocytes

  2005cited by this paper
• Direct Measurement of Peptide-Specific CD8+ T Cells Using HLA-A2:Ig Dimer for Monitoring the In Vivo Immune Response to a HER2/neu Vaccine in Breast and Prostate Cancer Patients

  2004cited by this paper
• Effect of dose on immune response in patients vaccinated with an her-2/neu intracellular domain protein--based vaccine.

  2004influential reference
• Electroporated DNA vaccine clears away multifocal mammary carcinomas in her-2/neu transgenic mice.

  2004cited by this paper
• Improved Immunogenicity of an Immunodominant Epitope of the Her-2/neu Protooncogene by Alterations of MHC Contact Residues1

  2004cited by this paper
• HER-2/neu-Specific Monoclonal Antibodies Collaborate with HER-2/neu-Targeted Granulocyte Macrophage Colony-Stimulating Factor Secreting Whole Cell Vaccination to Augment CD8+ T Cell Effector Function and Tumor-Free Survival in Her-2/neu-Transgenic Mice1

  2003cited by this paper
• Immunization of cancer patients with a HER-2/neu, HLA-A2 peptide, p369-377, results in short-lived peptide-specific immunity.

  2002cited by this paper
• Therapeutic potential of a reduced-intensity preparative regimen for allogeneic transplantation with cladribine, busulfan, and antithymocyte globulin against advanced/refractory acute leukemia/lymphoma.

  2002cited by this paper
• Antihuman epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab enhances cytolytic activity of class I-restricted HER2-specific T lymphocytes against HER2-overexpressing tumor cells.

  2002cited by this paper
• Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients.

  2001cited by this paper
• Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells.

  2000cited by this paper
• Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine.

  1999cited by this paper
• Major histocompatibility complex class I presentation of exogenous soluble tumor antigen fused to the B‐fragment of Shiga toxin

  1998cited by this paper
• Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines

  1995cited by this paper
• Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide.

  1995cited by this paper
• Existent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancer.

  1994cited by this paper
• * Joint first authors

  year unknowncited by this paper

• Enhanced anti-tumor immunity of vaccine combined with anti-PD-1 antibody in a murine bladder cancer model

  2022cites this paper
• Development of immunotherapy for high-grade gliomas: Overcoming the immunosuppressive tumor microenvironment

  2022cites this paper
• STxB as an Antigen Delivery Tool for Mucosal Vaccination

  2022cites this paper
• The Cellular and Chemical Biology of Endocytic Trafficking and Intracellular Delivery—The GL–Lect Hypothesis

  2021cites this paper
• Therapeutic Uses of Bacterial Subunit Toxins

  2021cites this paper
• HER2-Positive Breast Cancer Immunotherapy: A Focus on Vaccine Development

  2020cites this paper
• Immunotherapy for gliomas: shedding light on progress in preclinical and clinical development

  2020cites this paper
• Investigation of the combination of anti-PD-L1 mAb with HER2/neu-loaded dendritic cells and QS-21 saponin adjuvant: effect against HER2 positive breast cancer in mice

  2020cites this paper
• The adjuvant effect of melanin is superior to incomplete Freund’s adjuvant in subunit/peptide vaccines in mice

  2020cites this paper
• Therapeutic cancer vaccine: building the future from lessons of the past

  2018cites this paper
• [Cell complexity should be placed at the heart of cancer research].

  2018cites this paper
• Rapalog combined with CCR4 antagonist improves anticancer vaccines efficacy

  2018cites this paper
• Further insight into AE37 peptide vaccination in prostate cancer

  2017cites this paper
• Enhanced immune response induced by P5 HER2/neu‐derived peptide‐pulsed dendritic cells as a preventive cancer vaccine

  2017cites this paper
• MgAl-layered double hydroxide nanoparticles co-delivering siIDO and Trp2 peptide effectively reduce IDO expression and induce cytotoxic T-lymphocyte responses against melanoma tumor in mice.

  2017cites this paper
• Restoring Lost Anti-HER-2 Th1 Immunity in Breast Cancer: A Crucial Role for Th1 Cytokines in Therapy and Prevention

  2016cites this paper
• Is There Still Room for Cancer Vaccines at the Era of Checkpoint Inhibitors

  2016cites this paper